Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From record-breaking box-office weekends to multi-year theater signings in China, IMAX Corporation’s financial pulse beats inside its SEC disclosures. Each 10-K details giant-screen installs, backlog totals, and revenue splits with exhibitors, while every 10-Q revisits film remastering margins and technology licensing momentum. Yet these insights hide in hundreds of pages of technical language.
Stock Titan’s AI translates those dense documents the instant they appear on EDGAR. Want IMAX insider trading Form 4 transactions? Real-time alerts surface each executive trade. Need the most recent IMAX quarterly earnings report 10-Q filing? Our summaries highlight per-screen averages and joint-venture revenue in plain English. Coverage spans every critical form:
- 10-K annual report – network size, backlog, risk factors simplified
- 10-Q quarterly earnings with AI commentary and trend visuals
- 8-K material events – new studio partnerships and technology launches explained
- Proxy statement – IMAX proxy statement executive compensation decoded
- Form 4 – IMAX Form 4 insider transactions real-time
Professionals use these outputs to monitor screen-count expansion, evaluate royalty streams, and track incentive alignment through IMAX executive stock transactions Form 4. If you ask, “understanding IMAX SEC documents with AI” or search for “IMAX earnings report filing analysis,” this page delivers. Our AI keeps every IMAX annual report 10-K simplified and IMAX 8-K material events explained at your fingertips, saving hours and sharpening decisions.
IMAX (IMAX) executive Mark Welton reported an option exercise and share sale. On 11/10/2025, he exercised stock options into 49,504 common shares at $22.49 per share and sold 49,504 common shares at a price of $35.228.
Following these transactions, he beneficially owns 153,323 common shares directly. The filing notes 70,609 restricted share units outstanding after these transactions and that the options exercised were issued in 2019 and set to expire on March 7, 2026.
IMAX Chief Commercial Officer Giovanni M. Dolci reported an option exercise and same‑day sale. On 11/10/2025, he exercised 6,188 stock options at $22.49 and sold 6,188 common shares at a weighted average price of $34.2452, leaving 33,000 common shares held directly.
The options were issued in 2019 and are set to expire on March 7, 2026. The filing notes remaining restricted share units of 21,574 following these transactions.
IMAX (IMAX) reported an insider transaction by CTO & EVP Pablo Calamera. On 11/10/2025, he executed a sale coded “S” of 20,586 common shares at a price of $34.2255 per share. Following the sale, his beneficially owned common shares total 40,886, held directly.
The filing also notes remaining restricted share units of 32,863 after the reported transactions. This Form 4 reflects a routine insider share sale and updated holdings.
IMAX filed a Form 144 indicating a proposed sale of 20,586 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $704,566.14 and an approximate sale date of 11/10/2025.
The shares to be sold were acquired via restricted stock vesting under a registered plan: 17,586 on 03/07/2024 and 3,000 on 03/07/2023, each for services rendered. Shares outstanding were 53,798,934; this is a baseline figure, not the amount being offered.
IMAX reported a Form 144 notice for a proposed sale of 49,504 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $1,743,926.91 and an approximate sale date of 11/10/2025 on the NYSE. The shares were acquired on 11/10/2025 via the exercise of options under a registered plan, with payment in cash. As context, 53,798,934 shares were outstanding.
IMAX filed a Form 144 notice for a planned sale of 6,188 common shares. The filing lists Morgan Stanley Smith Barney as broker, an aggregate market value of $211,909.30, and an approximate sale date of 11/10/2025 on the NYSE.
The shares were acquired on 11/10/2025 through the exercise of options under a registered plan, with payment in cash. Shares outstanding were 53,798,934. The signer represents they do not know of undisclosed material adverse information about the company.
IMAX Corp (IMAX): Form 4 insider activity. On 11/07/2025, Chief Legal Officer and Sr. EVP Robert D. Lister exercised stock options to acquire 50,143 common shares at $22.49 pursuant to a Rule 10b5-1 plan dated June 11, 2025, then sold 50,143 shares at $34.6652 the same day. After these transactions, he directly beneficially owned 161,421 common shares. The filing notes remaining restricted share units of 70,609. The options were issued in 2019 and set to expire on March 7, 2026, and the derivative balance following these transactions is listed as 0.
IMAX — Form 144 notice of proposed sale: A holder filed to sell up to 50,143 shares of Class A Common on or about 11/07/2025 through Merrill Lynch on the NYSE, reflecting an aggregate market value of 1,738,215.
The shares to be sold were acquired on 11/07/2025 via an exercise of options under a registered plan, paid in cash. Over the prior three months, the person reported selling 20,000 shares on 09/15/2025 for gross proceeds of 656,029. Shares outstanding were 53,798,934.
IMAX Corporation completed a private Rule 144A sale of $250 million aggregate principal amount of 0.750% Convertible Senior Notes due 2030, including the full exercise of a $30 million option. The notes pay interest semi‑annually beginning May 15, 2026 and mature on November 15, 2030, unless earlier converted, redeemed, or repurchased.
Net proceeds are expected to be $241.1 million. IMAX plans to use the cash, along with cash on hand and borrowings under its credit facility, to fund capped call transactions and repurchase its 0.500% Convertible Senior Notes due 2026. The company agreed to repurchase $229.7 million principal of the 2026 notes for a total cash price of $276.0 million, including accrued interest.
The initial conversion rate is 23.5743 shares per $1,000 (conversion price ≈ $42.42) with customary adjustments; upon conversion, IMAX will settle in cash or cash plus shares. The capped call’s initial cap price is $57.1025 (a 75% premium to the November 3, 2025 close) and cost approximately $21.9 million. The notes are redeemable at IMAX’s option on or after November 20, 2028 if the share price exceeds 130% of the conversion price for the specified trading periods. An initial maximum of 7,661,650 shares may be issuable upon conversion based on the initial maximum conversion rate.
IMAX Corporation filed its Q3 2025 report, showing higher revenue and profit. Revenue for the quarter was $106.654 million, up from $91.452 million a year ago, as stronger image enhancement and maintenance services ($61.029 million) and technology rentals ($23.336 million) offset lower technology sales ($19.360 million). Gross margin rose to $67.271 million from $51.019 million, and income from operations increased to $29.045 million from $19.411 million.
Net income attributable to common shareholders was $20.657 million, or diluted EPS of $0.37, versus $13.896 million and $0.26 last year. Year‑to‑date operating cash flow reached $97.694 million, supporting cash and cash equivalents of $143.106 million as of September 30, 2025. Total assets were $889.573 million and total shareholders’ equity was $435.986 million. Debt consisted of $230.743 million in convertible notes and other borrowings and $26.477 million outstanding on the revolving credit facility. Deferred revenue increased to $64.505 million. Common shares outstanding were 53,798,934 as of September 30, 2025.
FAQ
What is the current stock price of Imax (IMAX)?
What is the market cap of Imax (IMAX)?
